AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker ...

(Reuters) -AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its ...

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...

This photo shows evidence of damage caused by long-term rheumatoid arthritis which was present before the newer anti-arthritic drugs became widely available. In addition to disease-modifying drugs, ...

In the last four months of 2024, the FDA tacked on nods for Bimzelx to treat psoriatic arthritis ... 12:55 p.m. ET The remarkable success of Skyrizi and Rinvoq has allowed AbbVie to accomplish ...

National Psoriasis Foundation. Published December 4, 2018. Lampner C. Managing Psoriatic Arthritis: Updated 2018 Recommendations From ACR/NPF. Published December 13, 2018. National Psoriasis ...

Skyrizi is an effective treatment option for plaque psoriasis, Crohn’s disease, ulcerative colitis, and psoriatic arthritis. Success rates may vary depending on the condition being treated and ...

The emergence of new treatments and therapeutic approaches for psoriatic arthritis is improving physicians’ ability to treat a complicated, multifaceted disease. This episode details how ...